Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
21 hedge funds and large institutions have $1.47M invested in Vyant Bio, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
9% less funds holding
Funds holding: 23 → 21 (-2)
42% less capital invested
Capital invested by funds: $2.54M → $1.47M (-$1.07M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$22.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$7.15K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.08K |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.81K |
| 5 |
Renaissance Technologies
New York
|
+$781 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cerity Partners
New York
|
-$171K |
| 2 |
BlackRock
New York
|
-$67.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$50K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8K |
| 5 |
TWMP
Taylor Wealth Management Partners
Boston,
Massachusetts
|
-$3K |
VYNT Hedge Fund Activity: Q2 2022 in Review
21 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q2 2022, worth a combined $1.47M — down 42% from $2.54M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of VYNT and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $22.5K. The largest seller was Cerity Partners, exiting entirely with an estimated $171K sold.
- 21 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q2 2022, down from 23 in Q1 2022.
- Funds reported $1.47M of Vyant Bio, Inc. Common Stock stock for Q2 2022, down 42% quarter-over-quarter.
- 2 funds opened new Vyant Bio, Inc. Common Stock positions in Q2 2022 and 4 closed out, a net change of -2 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q2 2022 was Virtu Financial, an estimated $22.5K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q2 2022 was Cerity Partners, an estimated $171K sold.
Based on aggregated 13F filings for Q2 2022.